How CGRP Drives Migraine: From Mechanism to Medicine

The short answer

Migraine research converged on calcitonin gene-related peptide, or CGRP, because this neuropeptide sits at the center of the trigeminovascular pathway that generates head pain. Sensory nerves release CGRP during attacks, infusing it can provoke migraine-like headache in susceptible people, and blocking either the peptide or its receptor lowers attack frequency in controlled trials. That mechanistic chain, built over decades, is what made CGRP a rational drug target rather than a fortunate accident. This article is educational and not medical advice.

The circuit that makes a headache

To understand why CGRP matters, start with the anatomy of migraine pain. The trigeminal nerve carries sensation from the face and the coverings of the brain, including the meninges and their blood vessels. When the peripheral endings of these sensory fibers are activated, they do two things at once: they send pain signals inward toward the brainstem, and they release neuropeptides locally at the vessel wall. This dual role, sensing and secreting, defines what researchers call the trigeminovascular system.

CGRP is one of the most abundant peptides in these fibers. As Edvinsson and Goadsby recount in their history of the field in Cephalalgia, the peptide was first identified in the 1980s, and within a few years investigators showed that it appears in the cranial venous outflow during acute migraine and cluster headache attacks. In other words, when someone has a migraine, measurable CGRP is being released from the trigeminal system. That observation reframed migraine from a purely vascular event into a disorder of sensory signaling with a specific molecular fingerprint.

From correlation to causation

A molecule appearing during an attack is suggestive, but correlation is not cause. Two further lines of evidence closed that gap.

First, provocation studies. Investigators found that infusing CGRP into people with migraine could trigger a delayed, migraine-like headache, while having far less effect in people without the condition. A molecule that rises during attacks and can also induce them behaves like a driver, not a bystander.

Second, receptor biology. CGRP acts through an unusual receptor complex: the calcitonin receptor-like receptor, or CLR, must pair with a small accessory protein called RAMP1 to form the canonical CGRP receptor. As the Cephalalgia analysis by Close and colleagues describes, CLR with RAMP1 is expressed in the cerebral cortex and vasculature, and CGRP can also engage the amylin-1 receptor, giving the peptide more than one route to signal. Mapping where these receptors sit, on vessels, on nerve endings, and within pain-processing centers, told researchers exactly where an intervention might act.

Cortical spreading depression enters the picture

Migraine with aura adds another layer. The aura is thought to reflect cortical spreading depression, a slow wave of intense neuronal firing followed by suppression that travels across the cortex. Close and colleagues examined how this wave connects to CGRP and reported that repeated spreading depression events increase CGRP gene expression and peptide levels across brain regions, and that cortical CGRP release can occur under the elevated potassium conditions that accompany the wave. Their work also indicated that CGRP antagonism can modulate how spreading depression propagates. That places CGRP not only at the peripheral vessel wall but potentially at the cortical events that begin an attack with aura, offering more than one plausible site of action.

Turning a target into medicines

A validated mechanism invites a therapeutic question: if CGRP signaling helps generate migraine, does interrupting it help prevent or abort attacks? Two distinct pharmacological strategies emerged to test this.

One approach uses monoclonal antibodies, large proteins engineered to bind either CGRP itself or its receptor and neutralize the signal. Because antibodies are big and long-lived, this class is used for prevention, given at intervals to reduce how often attacks occur. The other approach uses gepants, small-molecule antagonists that block the CGRP receptor and can be taken orally, suiting them to acute treatment and, for some agents, prevention. A review by Cohen and colleagues in BioDrugs summarizes that multiple CGRP-targeted antibodies and several gepants have reached regulatory approval, giving the mechanism two independent forms of pharmacological validation.

The trial evidence anchors this. In the STRIVE study published in the New England Journal of Medicine in 2017, Goadsby and colleagues tested the CGRP-receptor antibody erenumab against placebo in episodic migraine and reported a reduction in the number of monthly migraine days in the treated groups relative to placebo. The regulatory milestone followed: erenumab was approved in the United States in 2018 and is notable as the first approved antibody directed against a G-protein-coupled receptor, the CGRP receptor. When two structurally different interventions, an antibody and a small molecule, both reduce migraine by hitting the same pathway, the underlying biology gains considerable credibility.

What the mechanism does and does not claim

The CGRP story is a clean example of target validation moving from bench to clinic, but a few boundaries deserve emphasis. Blocking CGRP does not help everyone, which tells us migraine involves circuitry beyond this single peptide. The trials establish direction and category-level benefit, not a guarantee for any individual, and the choice of whether, when, and how to use any specific therapy is a clinical decision that depends on the whole person. The value of understanding the mechanism is not that it prescribes a treatment; it is that it explains why a class of treatments exists and what biology it engages.

What makes CGRP compelling as a scientific narrative is the completeness of the argument. The peptide is present in the right nerves, released during attacks, capable of provoking them, equipped with mapped receptors in pain-relevant tissue, linked to the cortical events of aura, and answerable to two independent drug classes in controlled trials. Each link was tested rather than assumed. That is what separates a durable drug target from a promising hypothesis.